Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
NCT04384692Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2020
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), sponsored by Fred Hutchinson Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04384692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384692.